OTLK (Outlook Therapeutics) Shares Outstanding (EOP): 104.61 Mil (As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
11 GF Score
Price $1.48
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics Shares Outstanding (EOP)?

Outlook Therapeutics OTLK -7.84% 11 Shares Outstanding (EOP) is 104.61 Mil as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Outlook Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 104.61 Mil.

Outlook Therapeutics's quarterly shares outstanding increased from Dec. 2025 (64.56 Mil) to Mar. 2026 (104.61 Mil). It means Outlook Therapeutics issued new shares from Dec. 2025 to Mar. 2026 .

Outlook Therapeutics's annual shares outstanding increased from Sep. 2024 (23.91 Mil) to Sep. 2025 (53.89 Mil). It means Outlook Therapeutics issued new shares from Sep. 2024 to Sep. 2025 .


Outlook Therapeutics  (NAS:OTLK) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Outlook Therapeutics Shares Outstanding (EOP) Related Terms


Outlook Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Shares Outstanding (EOP) Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.82 11.37 13.01 23.91 53.89

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.91 43.48 53.89 64.56 104.61

OTLK vs FULC, OBIO, ACIU: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Shares Outstanding (EOP) falls into.


OTLK
11GF Score
Outlook Therapeutics Inc OTLK
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 104.61 Mil mean?
Outlook Therapeutics (OTLK) has a Shares Outstanding (EOP) of 104.61 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' Shares Outstanding (EOP) too high?
Outlook Therapeutics' current Shares Outstanding (EOP) is 104.61 Mil. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Shares Outstanding (EOP) compare to FULC and OBIO?
Outlook Therapeutics' Shares Outstanding (EOP) of 104.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Shares Outstanding (EOP) is 104.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Shares Outstanding (EOP) of 104.61 Mil. The current Shares Outstanding (EOP) is 104.61 Mil. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Shares Outstanding (EOP) is 104.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score

Get the complete analysis for OTLK

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price